Silexion Therapeutics (SLXN) director granted 7,576 shares and 8,904 options
Rhea-AI Filing Summary
Peled Amnon reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp director Amnon Peled received equity awards from the company. On February 20, 2026, he was granted 7,576 ordinary shares at no cost through fully vested restricted share units issued for his director services.
On the same date, he was also granted stock options for 8,904 ordinary shares, with the options vesting in full one year after the board’s approval date and expiring ten years after that approval. An additional option holding of 780 shares was reported for informational purposes only, with no transactions effected in that line.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 7,576 shares
Net Buy
3 txns
Insider
Peled Amnon
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy Ordinary Shares) | 8,904 | $0.00 | $0.00 |
| Grant/Award | Ordinary Shares | 7,576 | $0.00 | $0.00 |
| holding | Stock Option (right to buy Ordinary Shares) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy Ordinary Shares) — 9,684 shares (Direct);
Ordinary Shares — 8,237 shares (Direct)
Footnotes (4)
- F1. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share, of the Issuer ("ordinary shares"), in respect of the Reporting Person's director services to the Issuer. The grant was approved by the Issuer's board of directors.
- F2. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of options to purchase ordinary shares, which grant was approved by the Issuer's board of directors.
- F3. The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.
- F4. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Silexion Therapeutics (SLXN) report for Amnon Peled?
Silexion reported that director Amnon Peled received equity awards, including ordinary shares and stock options, as compensation for his board service. These were structured as a share grant settled from RSUs and a separate option grant approved by the company’s board of directors.
What stock option grant did Amnon Peled receive from Silexion Therapeutics (SLXN)?
He was granted options to purchase 8,904 ordinary shares of Silexion Therapeutics. These options were approved by the board, vest entirely on the one-year anniversary of their approval date, and expire on the ten-year anniversary of that same approval date.
Were any of Amnon Peled’s Silexion Therapeutics (SLXN) transactions open-market buys or sells?
No open-market buying or selling was reported. The Form 4 describes grants of ordinary shares and stock options approved by the board as compensation, with a transaction code for grant or award, rather than purchases or sales on the open market.
What does the Form 4 say about the additional 780 Silexion Therapeutics (SLXN) options?
The Form 4 notes a holding of options over 780 ordinary shares, but explicitly states there were no transactions in that row. Those options are included only for informational purposes and do not represent a new grant, purchase, or sale.
Why did Silexion Therapeutics (SLXN) grant RSUs and options to director Amnon Peled?
The filing explains that the equity awards compensate Amnon Peled for his director services to Silexion. The RSUs, settled into ordinary shares, and the stock options were each granted pursuant to approvals by the Silexion Therapeutics board of directors.